Patient and physician factors driving the gaps in use of drugs with cardiovascular and kidney benefits by medicare beneficiaries with type 2 diabetes treated by endocrinologists, nephrologists, and cardiologists: Population-based cohort study
Authors' conclusion
Many, particularly older, patients with T2D treated by endocrinologists, nephrologists, and cardiologists should be, but are not, prescribed GLP-1RA/SGTL2i. Physician training may improve these statistics.
Study context
- Population
- Adults >65 years with T2D and coexisting cardiovascular disease (CVD), heart failure (HF) and/or chronic kidney disease (CKD) and their treating endocrinologists, nephrologists and cardiologists (Medicare, 2022)
- Participants
- 246,106 / 254,425 / 435,773
- Exposure
- GLP-1RA/SGLT2i use among patients treated by endocrinologists, nephrologists and cardiologists
- Endocrinologistsn = 246,106
- Nephrologistsn = 254,425
- Cardiologistsn = 435,773
- Outcome
- Patient and physician factors associated with GLP-1RA/SGLT2i use
- Follow-up
- 2022
Methodological detailspopulation-based, linked 2022 Medicare and American Board of Internal Medicine data
- Population-based
- Linked 2022 Medicare and American Board of Internal Medicine data
Main finding
As reported in the abstract
Filled GLP-1RA/SGLT2i
Observational data: associations, not effects.
Further findings
Filled diabetes medications prescribed by the subspecialist · 2022
Original publication
Patient and physician factors driving the gaps in use of drugs with cardiovascular and kidney benefits by medicare beneficiaries with type 2 diabetes treated by endocrinologists, nephrologists, and cardiologists: Population-based cohort study. Diabetes Res Clin Pract. Published 7 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →